
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc. is poised for significant growth due to its strategic clinical program pipeline and upcoming product introductions, including VK2735 and an amylin agonist IND, which are expected to enhance investor sentiment. The company’s advanced standing among independent late-stage metabolic players positions it favorably as the market for such assets becomes increasingly scarce. Additionally, Viking's maturity and data strength are likely to attract favorable partnership opportunities and financing terms, contributing to a positive long-term outlook.
Bears say
Viking Therapeutics Inc faces significant risks inherent to the biopharmaceutical industry, particularly concerning unexpected outcomes from clinical trials and regulatory uncertainties that could impede product development. Furthermore, the company operates in an increasingly complex and price-sensitive commercial landscape, which may hinder the profitability of its product candidates. The heightened scrutiny on licensing agreements, especially in U.S.-China contexts, adds another layer of challenge that may adversely affect Viking's strategic partnerships and growth potential.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares